12:00 AM
 | 
Mar 08, 2010
 |  BC Week In Review  |  Company News  |  Deals

Rigel, Merck KGaA deal

Merck informed Rigel that it plans to wind down ongoing trials and return rights to R763 (AS703569). The aurora kinase inhibitor is in Phase...

Read the full 97 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >